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M IS-C In pat ien t Algor it h m

Adm it pt t o In pt Un it
(Follow ?Initial Assessment? per MIS-C Evaluation and Treatment
algorithm if pt admitted from outside facility)

Is MIS-C
suspected from "Initial
Assessment"?
Com pen sat ed sh ock : persistent
tachycardia despite antipyretics, BP
may be normal or have wide pulse
pressure, intact peripheral perfusion or
brisk cap refill
Hypot en sive sh ock : tachycardia,
hypotension and/or wide pulse
pressure, delayed or flash peripheral
perfusion

Provide routine inpt management for diagnosis
OR
Discharge home with:
- PCP follow up in 24-48 hrs
AND
- Return to ED for fever ? 5 days and/or new
signs/symptoms

No

Yes

Does the pt
have either compensated
or hypotensive
shock?
No
Suspect MIS-C without Shock

Abbr eviat ion s (labor at or y &
r adiology exclu ded):
pt = patient
MIS-C = Multisystem inflammatory
syndrome in children
ED = Emergency Department
PICU = Pediatric Intensive Care Unit

Suspect MIS-C with Compensated or
Hypotensive Shock

Yes

* Initiate MIS-C Inpt PowerPlan
Labs:
- Draw Tier 1/Tier 2 labs per MIS-C Evaluation and
Treatment algorithm if not already obtained
Diagn ost ic St u dies:
- Obtain ECG, ECHO* (non-urgent)
* consider PICU transfer if moderate or severe cardiac
dysfunction on ECHO
Con su lt :
- Infectious Diseases
- Rheumatology
- Cardiology
- Coag: If Tier 2 labs abnormal OR clinical suspicion for
MIS-C
M edicat ion s:
- PPI for GI Prophylaxis
- Fluid resuscitation as clinically indicated
- VTE Prophylaxis per COVID-19 VTE Prophylaxis
Guidelines
- Additional treatment per consultant
recommendations

-

Tr an sf er t o PICU
(DO NOT delay transfer while
initiating following therapies):
Initiate Sepsis Inpt PowerPlan
Initiate MIS-C Inpt PowerPlan
Administer 20 ml/kg NS bolus, reassess after
each bolus to avoid fluid overload
Obtain VBG, Tier 1 and Tier 2 labs, CXR, ECG,
ECHO (urgent) if not already obtained
Antibiotics per MIS-C Inpt PowerPlan
(cefepime, vancomycin, doxycycline)
Consult:
- Infectious Diseases
- Rheumatology
- Cardiology
- Coag: If Tier 2 labs abnormal OR clinical
suspicion for MIS-C

No

Yes

Is pt stable for
transfer to
Medical Unit?

No

Does pt
meet discharge
criteria?

Disch ar ge Cr it er ia:
- Minimum observation for 24 hours is recommended
- Hemodynamically stable ?48 hours
- Improved or normal cardiac function
- Afebrile?48 hours
- Down-trending inflammatory markers
- Improving or stable end organ involvement

Yes
Discharge pt after Outpt Follow-Up/Issues determined:
- Discuss need for Aspirin therapy at discharge with consulting teams
- Follow-up with PCP in 24-48 hours
- Follow-up with Rheumatology if pt received steroids, anakinra, immune modulation beyond IVIG, concern for MAS, or
provider discretion
- Follow-up with Infectious Diseases if ongoing treatment for infection or treated with IVIG alone
- Follow-up with cardiology at 2 weeks and 6 weeks following discharge
- Follow-up with Coag if thrombus identified or pt continuing on
prophylactic anticoagulation at the time of discharge
- Return to ED for fever ?5 days and/or new signs/symptoms
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This care process model/clinical practice guideline is meant as a guide for the healthcare provider, does not establish a standard of care, and is not a substitute for medical judgment
which should be applied based upon the individual circumstances and clinical condition of the patient.

